Lixte Cash per Share

LIXT -  USA Stock  

USD 1.86  0.01  0.53%

Lixte Biotech Hlds fundamentals help investors to digest information that contributes to Lixte Biotech's financial success or failures. It also enables traders to predict the movement of Lixte Stock. This fundamental analysis module provides a way for investors to measures Lixte Biotech's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotech stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lixte Cash per Share 

 
Refresh

Lixte Cash per Share Analysis

Lixte Biotech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cash per Share 
 = 
Total Cash 
Average Shares 
More About Cash per Share | All Equity Analysis

Current Lixte Biotech Cash per Share

    
  0.50 X  
Most of Lixte Biotech's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotech Hlds is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Compare to competition

In accordance with the recently published financial statements, Lixte Biotech Hlds has a Cash per Share of 0.5 times. This is 88.51% lower than that of the Healthcare sector and 88.45% lower than that of the Biotechnology industry. The cash per share for all United States stocks is 90.02% higher than that of the company.

Lixte Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotech's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotech could also be used in its relative valuation, which is a method of valuing Lixte Biotech by comparing valuation metrics of similar companies.
Lixte Biotech is currently under evaluation in cash per share category among related companies.

Lixte Fundamentals

About Lixte Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotech Hlds's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotech Hlds based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lixte Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lixte Biotech Hlds using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Lixte Biotech Piotroski F Score and Lixte Biotech Altman Z Score analysis. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Lixte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotech. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.